News|Articles|August 8, 2024
Biopharmaceutical Frontiers
Author(s)Solvias
Daniel Galbraith, Chief Scientific Officer (CSO) of Solvias provided a comprehensive picture to Pharmaceutical Technology of the current landscape of cell and gene therapy advancements. The discussion covers important regulatory guidance, technological landmarks, and how Solvias is impacting the current market.
Related Content
Trending on Pharmaceutical Technology
1
Technology Transfer: Success Drivers and Obstacles Explained
2
Assessment of Silicone Oil Cleaning on Indirect Surfaces in Aseptic Manufacturing
3
Shilpa CDMO to Launch as Dedicated Complex Small-Molecule Contract Development and Manufacturing Brand at CPHI Milan
4
European Regulators Prepare the Pharma Industry for Future Changes as Legislation is Formalized
5